Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Myriad Genetics Q4 2023 Adj EPS $0.04 Beats $0.01 Estimate, Sales $196.60M Beat $194.78M Estimate

Author: Benzinga Newsdesk | February 27, 2024 05:47pm
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. The company reported quarterly sales of $196.60 million which beat the analyst consensus estimate of $194.78 million by 0.93 percent. This is a 10.57 percent increase over sales of $177.80 million the same period last year.

Posted In: MYGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist